NCT02840474View on ClinicalTrials.gov

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

January 15, 2020

Study Completion Date

January 15, 2020

Conditions
HIV-1
Interventions
BIOLOGICAL

VRC-HIVMAB080-00-AB

VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.

BIOLOGICAL

VRC-HIVMAB075-00-AB

VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.

Trial Locations (7)

35294

University of Alabama HIV Clinic Clinical Research Site, AIDS Clinical Trials Group (ACTG), Birmingham

43210

Ohio State University Clinical Research Site, AIDS Clinical Trials Group (ACTG), Columbus

45267

University of Cincinnati University Hospital, AIDS Clinical Trials Group (ACTG), Cincinnati

63110

Washington University Therapeutics, AIDS Clinical Trials Group (ACTG), St Louis

90035

UCLA CARE Center, AIDS Clinical Trials Group (ACTG), Los Angeles

19104-6056

Hospital of the University of Pennsylvania Clinical Research Site, AIDS Clinical Trials Group (ACTG), Philadelphia

00935

Puerto Rico AIDS Clinical Trials Unit, AIDS Clinical Trials Group (ACTG), San Juan

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02840474 - Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults | Biotech Hunter | Biotech Hunter